Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: Effect of contrast material flow rate

Wolfgang Schima, Renate Hammerstingl, Carlo Catalano, Luis Marti-Bonmati, Ernst J. Rummeny, Francisco Tardáguila Montero, Albert Dirisamer, Bernd Westermayer, Massimo Bellomi, Denis Brisbois, Patrick Chevallier, Martin Dobritz, Jacques Drouillard, Francesco Fraioli, Maria Jesus Martinez, Sandro Morassut, Thomas J. Vogl

Research output: Contribution to journalArticle

Abstract

OBJECTIVE. The purposes of this study were to evaluate the effect of contrast material flow rate (3 mL/sec vs 5 mL/sec) on the detection and visualization of hepatocellular carcinoma (HCC) with MDCT and the safety profile of iodixanol at different injection rates. SUBJECTS AND METHODS. In a prospective, randomized multicenter trial, 97 patients (83 men and 14 women, with a mean age of 64 years) suspected of having HCC underwent quadruple-phase (double arterial, portal venous, delayed phase) 4- 16-MDCT. Patients were randomized to receive iodixanol, 320 mg I/mL (1.5 mL/kg body weight), at a flow rate of 3 mL/sec (48 patients) or 5 mL/sec (49 patients). Qualitative (lesion detection, image quality) and quantitative (liver and aortic enhancement, tumor-liver contrast) analyses and safety assessment were performed. RESULTS. Overall, 145 HCCs were detected in the 5 mL/sec group and 100 HCCs in the 3 mL/sec group (p <0.05). More lesions equal to or less than 1 cm were detected at 5 mL/sec (33 vs 16 lesions). The late arterial phase showed significantly more lesions than the early, arterial phase (133 vs 100 and 96 vs 67 lesions, respectively, p <0.0001). Hyperattenuating HCCs were better visualized in the late arterial phase at 5 mL/sec (excellent visualization: 54% vs 27%). Using a flow of 5 mL/sec did not increase the rate of patient discomfort or contrast media-related adverse events. Most discomfort in both groups was of mild intensity and there was no severe discomfort. CONCLUSION. For detection of HCC with MDCT, a higher flow rate of 5 mL/sec is recommended. Visualization of hyperattenuating HCC is improved with no greater discomfort or adverse events.

Original languageEnglish
Pages (from-to)1571-1579
Number of pages9
JournalAmerican Journal of Roentgenology
Volume186
Issue number6
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Contrast Media
Hepatocellular Carcinoma
Liver
Safety
Multicenter Studies
Body Weight
Injections
Neoplasms
iodixanol

Keywords

  • Contrast media
  • CT
  • Liver disease
  • MDCT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Schima, W., Hammerstingl, R., Catalano, C., Marti-Bonmati, L., Rummeny, E. J., Montero, F. T., ... Vogl, T. J. (2006). Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: Effect of contrast material flow rate. American Journal of Roentgenology, 186(6), 1571-1579. https://doi.org/10.2214/AJR.05.1226

Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma : Effect of contrast material flow rate. / Schima, Wolfgang; Hammerstingl, Renate; Catalano, Carlo; Marti-Bonmati, Luis; Rummeny, Ernst J.; Montero, Francisco Tardáguila; Dirisamer, Albert; Westermayer, Bernd; Bellomi, Massimo; Brisbois, Denis; Chevallier, Patrick; Dobritz, Martin; Drouillard, Jacques; Fraioli, Francesco; Martinez, Maria Jesus; Morassut, Sandro; Vogl, Thomas J.

In: American Journal of Roentgenology, Vol. 186, No. 6, 06.2006, p. 1571-1579.

Research output: Contribution to journalArticle

Schima, W, Hammerstingl, R, Catalano, C, Marti-Bonmati, L, Rummeny, EJ, Montero, FT, Dirisamer, A, Westermayer, B, Bellomi, M, Brisbois, D, Chevallier, P, Dobritz, M, Drouillard, J, Fraioli, F, Martinez, MJ, Morassut, S & Vogl, TJ 2006, 'Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: Effect of contrast material flow rate', American Journal of Roentgenology, vol. 186, no. 6, pp. 1571-1579. https://doi.org/10.2214/AJR.05.1226
Schima, Wolfgang ; Hammerstingl, Renate ; Catalano, Carlo ; Marti-Bonmati, Luis ; Rummeny, Ernst J. ; Montero, Francisco Tardáguila ; Dirisamer, Albert ; Westermayer, Bernd ; Bellomi, Massimo ; Brisbois, Denis ; Chevallier, Patrick ; Dobritz, Martin ; Drouillard, Jacques ; Fraioli, Francesco ; Martinez, Maria Jesus ; Morassut, Sandro ; Vogl, Thomas J. / Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma : Effect of contrast material flow rate. In: American Journal of Roentgenology. 2006 ; Vol. 186, No. 6. pp. 1571-1579.
@article{9db8a625b62743d191ebc34079b5e086,
title = "Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: Effect of contrast material flow rate",
abstract = "OBJECTIVE. The purposes of this study were to evaluate the effect of contrast material flow rate (3 mL/sec vs 5 mL/sec) on the detection and visualization of hepatocellular carcinoma (HCC) with MDCT and the safety profile of iodixanol at different injection rates. SUBJECTS AND METHODS. In a prospective, randomized multicenter trial, 97 patients (83 men and 14 women, with a mean age of 64 years) suspected of having HCC underwent quadruple-phase (double arterial, portal venous, delayed phase) 4- 16-MDCT. Patients were randomized to receive iodixanol, 320 mg I/mL (1.5 mL/kg body weight), at a flow rate of 3 mL/sec (48 patients) or 5 mL/sec (49 patients). Qualitative (lesion detection, image quality) and quantitative (liver and aortic enhancement, tumor-liver contrast) analyses and safety assessment were performed. RESULTS. Overall, 145 HCCs were detected in the 5 mL/sec group and 100 HCCs in the 3 mL/sec group (p <0.05). More lesions equal to or less than 1 cm were detected at 5 mL/sec (33 vs 16 lesions). The late arterial phase showed significantly more lesions than the early, arterial phase (133 vs 100 and 96 vs 67 lesions, respectively, p <0.0001). Hyperattenuating HCCs were better visualized in the late arterial phase at 5 mL/sec (excellent visualization: 54{\%} vs 27{\%}). Using a flow of 5 mL/sec did not increase the rate of patient discomfort or contrast media-related adverse events. Most discomfort in both groups was of mild intensity and there was no severe discomfort. CONCLUSION. For detection of HCC with MDCT, a higher flow rate of 5 mL/sec is recommended. Visualization of hyperattenuating HCC is improved with no greater discomfort or adverse events.",
keywords = "Contrast media, CT, Liver disease, MDCT",
author = "Wolfgang Schima and Renate Hammerstingl and Carlo Catalano and Luis Marti-Bonmati and Rummeny, {Ernst J.} and Montero, {Francisco Tard{\'a}guila} and Albert Dirisamer and Bernd Westermayer and Massimo Bellomi and Denis Brisbois and Patrick Chevallier and Martin Dobritz and Jacques Drouillard and Francesco Fraioli and Martinez, {Maria Jesus} and Sandro Morassut and Vogl, {Thomas J.}",
year = "2006",
month = "6",
doi = "10.2214/AJR.05.1226",
language = "English",
volume = "186",
pages = "1571--1579",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "6",

}

TY - JOUR

T1 - Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma

T2 - Effect of contrast material flow rate

AU - Schima, Wolfgang

AU - Hammerstingl, Renate

AU - Catalano, Carlo

AU - Marti-Bonmati, Luis

AU - Rummeny, Ernst J.

AU - Montero, Francisco Tardáguila

AU - Dirisamer, Albert

AU - Westermayer, Bernd

AU - Bellomi, Massimo

AU - Brisbois, Denis

AU - Chevallier, Patrick

AU - Dobritz, Martin

AU - Drouillard, Jacques

AU - Fraioli, Francesco

AU - Martinez, Maria Jesus

AU - Morassut, Sandro

AU - Vogl, Thomas J.

PY - 2006/6

Y1 - 2006/6

N2 - OBJECTIVE. The purposes of this study were to evaluate the effect of contrast material flow rate (3 mL/sec vs 5 mL/sec) on the detection and visualization of hepatocellular carcinoma (HCC) with MDCT and the safety profile of iodixanol at different injection rates. SUBJECTS AND METHODS. In a prospective, randomized multicenter trial, 97 patients (83 men and 14 women, with a mean age of 64 years) suspected of having HCC underwent quadruple-phase (double arterial, portal venous, delayed phase) 4- 16-MDCT. Patients were randomized to receive iodixanol, 320 mg I/mL (1.5 mL/kg body weight), at a flow rate of 3 mL/sec (48 patients) or 5 mL/sec (49 patients). Qualitative (lesion detection, image quality) and quantitative (liver and aortic enhancement, tumor-liver contrast) analyses and safety assessment were performed. RESULTS. Overall, 145 HCCs were detected in the 5 mL/sec group and 100 HCCs in the 3 mL/sec group (p <0.05). More lesions equal to or less than 1 cm were detected at 5 mL/sec (33 vs 16 lesions). The late arterial phase showed significantly more lesions than the early, arterial phase (133 vs 100 and 96 vs 67 lesions, respectively, p <0.0001). Hyperattenuating HCCs were better visualized in the late arterial phase at 5 mL/sec (excellent visualization: 54% vs 27%). Using a flow of 5 mL/sec did not increase the rate of patient discomfort or contrast media-related adverse events. Most discomfort in both groups was of mild intensity and there was no severe discomfort. CONCLUSION. For detection of HCC with MDCT, a higher flow rate of 5 mL/sec is recommended. Visualization of hyperattenuating HCC is improved with no greater discomfort or adverse events.

AB - OBJECTIVE. The purposes of this study were to evaluate the effect of contrast material flow rate (3 mL/sec vs 5 mL/sec) on the detection and visualization of hepatocellular carcinoma (HCC) with MDCT and the safety profile of iodixanol at different injection rates. SUBJECTS AND METHODS. In a prospective, randomized multicenter trial, 97 patients (83 men and 14 women, with a mean age of 64 years) suspected of having HCC underwent quadruple-phase (double arterial, portal venous, delayed phase) 4- 16-MDCT. Patients were randomized to receive iodixanol, 320 mg I/mL (1.5 mL/kg body weight), at a flow rate of 3 mL/sec (48 patients) or 5 mL/sec (49 patients). Qualitative (lesion detection, image quality) and quantitative (liver and aortic enhancement, tumor-liver contrast) analyses and safety assessment were performed. RESULTS. Overall, 145 HCCs were detected in the 5 mL/sec group and 100 HCCs in the 3 mL/sec group (p <0.05). More lesions equal to or less than 1 cm were detected at 5 mL/sec (33 vs 16 lesions). The late arterial phase showed significantly more lesions than the early, arterial phase (133 vs 100 and 96 vs 67 lesions, respectively, p <0.0001). Hyperattenuating HCCs were better visualized in the late arterial phase at 5 mL/sec (excellent visualization: 54% vs 27%). Using a flow of 5 mL/sec did not increase the rate of patient discomfort or contrast media-related adverse events. Most discomfort in both groups was of mild intensity and there was no severe discomfort. CONCLUSION. For detection of HCC with MDCT, a higher flow rate of 5 mL/sec is recommended. Visualization of hyperattenuating HCC is improved with no greater discomfort or adverse events.

KW - Contrast media

KW - CT

KW - Liver disease

KW - MDCT

UR - http://www.scopus.com/inward/record.url?scp=33745491789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745491789&partnerID=8YFLogxK

U2 - 10.2214/AJR.05.1226

DO - 10.2214/AJR.05.1226

M3 - Article

C2 - 16714645

AN - SCOPUS:33745491789

VL - 186

SP - 1571

EP - 1579

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 6

ER -